Mituhiko Moriyama
Nihon University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mituhiko Moriyama.
Digestion | 2008
Ryu Nishiyama; Noriko Nakajima; Akifumi Ogihara; Souichirou Oota; Shun Kobayashi; Kiyoshi Yokoyama; Masahiko Oonishi; Shunpachi Miyamoto; Yuuichi Akai; Toshikazu Watanabe; Akitake Uno; Shigeaki Mizuno; Takeshi Ootani; Naohide Tanaka; Mituhiko Moriyama
Background/Aims: Schönlein-Henoch purpura (SHP) is a systemic condition characterized by purpura associated with leukocytoclastic vasculitis. SHP diagnosis is more difficult in infrequent cases where gastrointestinal (GI) symptoms precede purpura. This report examines 11 cases of SHP at our hospital with specific regard to the incidences and details of GI symptoms. Methods: The clinical manifestations and endoscopic findings were investigated for their utility in SHP diagnosis. Results: Among the 11 cases, 3 showed GI symptoms prior to other manifestations. In terms of GI symptoms, abdominal pain was reported in all 11 cases, diarrhea in 4 cases, and bloody stools in 3 cases. Endoscopic findings were seen in the stomach in 7/10 cases, in the small intestine including the duodenum in 10/11 cases, and in the large intestine in 6/10 cases. The frequency of ulcer formation was significantly higher in the small intestine (including the duodenum) than in the stomach. Multiple specific erythematosus lesions were observed in the stomach and large intestine. Conclusion: Familiarity with characteristic endoscopic findings and careful observation of all GI findings are essential for diagnosing SHP in cases in which GI tract symptoms precede cutaneous findings.
Bioscience, Biotechnology, and Biochemistry | 2010
Tomoe Komoriya; Maho Kikuchi; Yutaka Terashima; Mayumi Okamoto; Masahiro Ogawa; Mituhiko Moriyama; Hideki Kohno
C-Reactive protein (CRP) is an acute-phase protein that increases during systemic inflammation and is currently one of the most frequently studied inflammatory markers in epidemiology. We have determined CRP concentration using novel latex reagent with polyclonal antibody. In the present study, we determined the concentration of CRP using monoclonal antibodies, and evaluated the interaction of antigen-antibody reactive sites and latex agglutination to detect low CRP concentrations. We developed four novel monoclonal antibodies that we classified into two major groups, and that were used to prepare the latex reagents. The latex reagents prepared using a cocktail of monoclonal antibodies for different epitopes appeared highly sensitive. The lower limit of CRP detection, which was defined using the mean 3 SD method, was calculated to be 5 ng/ml for the latex reagents when oligoclonal antibodies were utilized. Furthermore, the latex reagents were found to react specifically with CRP in clinical samples.
International Hepatology Communications | 1996
Fumihiko Komine; Mituhiko Moriyama; Nakanobu Hayashi; Toshikazu Uchida; Toshio Shikata; Yasuyuki Arakawa
Abstract We measured the levels of three antibodies against core (JCC-2), E1 (E1–5), and E2 NS1 (E2-1) hepatitis C virus (HCV) before and after interferon (IFN) therapy in 22 patients with chronic hepatitis C and assessed the relationship between the changes in these antibody titers and the response to IFN. The titers of serum JCC-2 and E2-1 antibodies before the IFN therapy did not show any significant relationship with IFN efficacy. In contrast, the titer of E1–5 antibody was significantly lower in the complete responder (CR) group than in the non-responder (NR) group. The JCC-2 antibody titer of the CR group to IFN therapy showed a significant decrease immediately, at 6 months and 1 year after the completion of IFN administration. However, that of the NR group either did not change or rose again 6 months or 1 year after therapy following an immediate short-term decrease. Thus the E1–5 antibody titer before IFN therapy and the JCC-2 antibody titer during IFN therapy seems to be a good indicator of IFN efficacy. In contrast, the E2-1 antibody did not correlate with IFN efficacy.
Pediatric Dermatology | 2010
Midori Nishio; Ryu Nishiyama; Yuichi Akai; Takeshi Otani; Naoto Kunoki; Taichi Nakagawa; Katsuhiko Shiozawa; Masahiko Onishi; Kiichi Hiroi; Toshikazu Watanabe; Masahiro Ogawa; Noriko Nakajima; Naohide Tanaka; Mituhiko Moriyama
Ultrasound in Medicine and Biology | 2009
Masahiro Ogawa; Risa Tohne; Shu Ohshiro; H. Ishiwata; Yoshiki Ono; Yoshinobu Yamamoto; Mituhiko Moriyama; Hiroashi Hashimoto
Ultrasound in Medicine and Biology | 2009
Ryu Nishiyama; Masahiro Ogawa; Taichi Nakagawa; Naoto Kunoki; Hisako Abe; Takeshi Otani; Naohide Tanaka; Mituhiko Moriyama
Pediatric Dermatology | 2009
Kiyoshi Itou; Shun Kobayashi; Hitomi Ryuzaki; Akiko Hosoi; Toshiki Yamamoto; Ryu Nishiyama; Toshikazu Watanabe; Takeshi Ootani; Akihumi Ogihara; Takashi Hirai; Etu Kohashi; Naohide Tanaka; Mituhiko Moriyama; Noriko Kinukawa
Pediatric Dermatology | 2009
Taichi Nakagawa; Ryu Nishiyama; Naoto Kunoki; Hisako Abe; Hitomi Ryuzaki; Soichirou Ota; Shun Kobayashi; Toshiki Yamamoto; Takeshi Otani; Masahiro Ogawa; Noriko Nakajima; Naohide Tanaka; Mituhiko Moriyama
Pediatric Dermatology | 2009
Satoko Watanabe; Ryu Nishiyama; Takeshi Ootani; Keiko Tachibana; Midori Nishio; Masahisa Abe; Naoki Matumoto; Masahiro Ogawa; Akifumi Ogihara; Noriko Nakajima; Naohide Tanaka; Mituhiko Moriyama
Pediatric Dermatology | 2009
Daisuke Koushi; Shigeaki Mizuno; Taiti Nakagawa; Maho Iwamoto; Syunpati Miyamoto; Hideki Satou; Yuuiti Akai; Kimitoshi Katou; Teruaki Matui; Mituhiko Moriyama